BEIGENE
Founded in 2010, BeiGene is a global biotechnology company that discovers and develops innovative oncology treatments and aims to make their medicines more accessible and affordable to cancer patients worldwide. The company has more than 9,200 colleagues globally and administrative offices on three continents, as well as one of the largest oncology research teams in the world. BeiGene continues to expand its broad in-house internal clinical development capabilities to make its therapies more av... ailable for patients around the globe. BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, is currently under review by regulators in the U.S. and the EU for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The company’s broad and deep pipeline has the potential to address 80 of cancers by incidence. Adjacent to its product portfolio and pipeline, the company also sponsors programs aimed at serving the broader needs of oncology patients, such as a program to raise awareness of mental health resources for people and families affected by cancer.
BEIGENE
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.beigene.com
Total Employee:
10001+
Status:
Active
Contact:
+1 (877) 828-5568
Email Addresses:
[email protected]
Total Funding:
6.79 B USD
Technology used in webpage:
Domain Not Resolving LetsEncrypt Amazon IPv6 ReCAPTCHA Pound Sterling Apple Mobile Web App Capable ASP.NET IIS Microsoft
Similar Organizations
Avadim Health
Avadim Health is a healthcare and wellness company.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
IgGenix
IgGenix is a biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hillhouse Investment
Hillhouse Investment investment in Post-IPO Equity - BeiGene
Amgen Ventures
Amgen Ventures investment in Post-IPO Equity - BeiGene
GIC
GIC investment in Post-IPO Equity - BeiGene
Amgen
Amgen investment in Post-IPO Equity - BeiGene
Rock Springs Capital
Rock Springs Capital investment in Series B - BeiGene
Hillhouse Investment
Hillhouse Investment investment in Series B - BeiGene
T. Rowe Price
T. Rowe Price investment in Series B - BeiGene
Hillhouse Investment
Hillhouse Investment investment in Series A - BeiGene
CITIC Capital Holdings
CITIC Capital Holdings investment in Series A - BeiGene
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-06-28 | Recorna Bio | BeiGene investment in Seed Round - Recorna Bio | N/A |
| 2023-02-08 | Duo Oncology | BeiGene investment in Seed Round - Duo Oncology | 3 M USD |
| 2021-11-02 | Shoreline Biosciences | BeiGene investment in Series B - Shoreline Biosciences | 140 M USD |
| 2021-06-23 | Strand Therapeutics | BeiGene investment in Series A - Strand Therapeutics | 52 M USD |
| 2021-03-17 | Boston Immune Technologies & Therapeutics | BeiGene investment in Series A - Boston Immune Technologies & Therapeutics | 10 M USD |
| 2020-12-01 | Singlomics | BeiGene investment in Series A - Singlomics | N/A |
| 2020-01-03 | Leap Therapeutics | BeiGene investment in Post-IPO Equity - Leap Therapeutics | 27 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-18 | BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer |
Official Site Inspections
http://www.beigene.com Semrush global rank: 1.25 M Semrush visits lastest month: 22.27 K
Unable to get host informations!!!
More informations about "BeiGene"
About Us - Beigene
This is vital as we continue to develop BeiGene in Canada with the goal of bringing innovative, affordable, and accessible treatments to patients and clinicians. Our people are truly our most valuable asset, and creating a …See details»
BeOne - Wikipedia
BeiGene was founded in late 2010 by John V. Oyler, [11] an American entrepreneur who serves as the company's chief executive officer and chairman, [30] alongside Xiaodong Wang, a …See details»
BeiGene - The Org
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 …See details»
Our Science & Development | BeiGene - BeiGene Nordics
Discover BeiGene's innovative cancer research and development. Learn about our science, global clinical trials, and advancements. Explore more now! ... to cancer biology unites cutting-edge research models and processes for drug …See details»
BeiGene - Crunchbase Company Profile & Funding
BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, …See details»
BeiGene Org Chart + Executive Team - The Official Board
Organizational Chart of BeiGene. BeiGene Org Chart www.beigene.com. has 65 executives and 2 subsidiaries +86 105 895 8000; Add an executive. Latest news on BeiGene (6160) Anything missing? We search for you. Print or download …See details»
Leadership & Board - BeiGene
Xiaodong Wang, Ph.D. is a co-founder of BeiGene and has served as Chairman of our Scientific Advisory Board since 2011. Dr. Wang has been on the Board of Directors since February …See details»
BeiGene Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 BeiGene has 5 employees across 19 locations and $3.81 b in annual revenue in FY 2024. See insights on BeiGene including office locations, competitors, revenue, financials, …See details»
What We Do - Beigene
BeiGene is focused on creating impactful medicines intended to be accessible to far more patients here in Canada and around the world. We are advancing an innovative, high-value product portfolio primarily targeting blood cancers and …See details»
Our History | BeiGene
Learn about BeiGene's growth and achievements in cancer treatment from 2010 to now. Explore our history and commitment to global health. Find out more!See details»
BeiGene to Present at the RBC Capital Markets Global Healthcare …
2 days ago SAN CARLOS, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne …See details»
Our Mission, Vision & Values - BeiGene
Mission. Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and …See details»
Who We Are - Beigene
BeiGene Canada is the Canadian affiliate of BeiGene Inc., a global biotechnology company developing and commercializing innovative and affordable cancer medicines to improve …See details»
Brand Evolution | BeiGene
The power button within the last “e” represents our always “on” approach in pursuing novel medicines that turn cancer “off” by disrupting key drivers of cancer cell growth and survival, …See details»
FAQs | BeiGene
BeiGene’s TEVIMBRA, a humanized monoclonal antibody directed against the immune checkpoint receptor PD-1, is approved for the treatment of various solid tumors across the …See details»
Our Mission, Vision & Values | BeiGene - BeiGene Nordics
Mission. Build the first next-generation biotechnology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, …See details»
Biotech Leader, BeiGene, Inaugurates Office in Toronto, Canada
May 8, 2024 New Office in Canada Signals BeiGene’s Commitment to Innovating Cancer Care for Canadians. Toronto, May 7, 2024 – BeiGene Canada, the country affiliate of global …See details»
Diversity, Equity, Inclusion & Belonging - BeiGene
Specific to global gender parity, BeiGene supports the UN’s Women’s Empowerment Principles (WEP) which provides a strong framework to support companies when striving for gender …See details»
Partnerships - Beigene
BeiGene is proud to be a member of BIOQuébec, Québec’s life science organization committed to supporting Québec’s biotechnology and life sciences industry, which creates wealth and …See details»
BeiGene | BeiGene's R&D Model
Leading with Science to Transform Cancer Care By Lai Wang, PhD, Global Head of R&D; August 2024 At BeiGene our research and development goal is clear: to lead with science and …See details»